Screening In-Depth Focus 2013
Posted: 30 July 2013 | European Pharmaceutical Review
In this Screening In-Depth Focus: New approaches to cell based assays for high content screening and analysis; Reduce, reuse, recycle: how drug repositioning is finding its niche in drug discovery; Workshop Review: Biochemical assays for screening.
- New approaches to cell based assays for high content screening and analysis
(Anthony Mitchell Davies, Director Irish National Centre for High Content Screening and Analysis (INCHSA), Department Clinical Medicine, Trinity College Dublin / Alice Vajda, Postdoctoral researcher, Department of Clinical Medicine, Trinity College Dublin / Sarah Louise Ryan, Laboratory Manager, Biocroi Ltd / Laure Marignol, Assistant Professor, Discipline of Radiation Therapy, Trinity College Dublin)
High content screening and analysis (HCS/A) technologies have become widely adopted in both the academic and industrial research sectors over the last 10 years. The acceptance of these technologies has in the large part been due to their demonstrable utility as both drug-discovery and basic research tools, indeed these imaging technologies such as HCS/A have the capability of providing researchers with a ready means of performing both large-scale primary screens as well as permitting more detailed downstream analysis…
- Workshop Review: Biochemical assays for screening
(Sheraz Gul, European ScreeningPort)
Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide now that host infrastructure such as compound libraries and automated screening centres. An archetypal small molecule drug discovery project will aim to identify chemical starting points that modify the functions of genes, cells or biochemical pathways. In some instances, these functions may be linked to disease processes and an opportunity will exist to further develop the probes into novel therapeutic agents. In small molecule drug discovery, the ultimate aim is to identify new therapeutics, an activity which for reasons of high risk and cost has historically been conducted within the commercial sectors…
- Reduce, reuse, recycle: how drug repositioning is finding its niche in drug discovery
(Emma J. Shanks, Head of Screening, The Beatson Institute for Cancer Research)
Despite continued and increased investment in R&D in recent decades, pharmaceutical companies have not delivered a proportionate number of truly innovative new drugs, but lack of success in transporting a drug through the entire drug development pipeline and delivering it to market does not necessarily equate with a wasted effort. In its journey, a drug will have been refined from a small molecule entity into a drug-like molecule with a strong affinity for its predicted target and a clear pharmacokinetic profile; thus, failure in clinical trials is predominantly observed as lack of efficacy against the intended disease indication rather than attributed to high toxicity or poor bioavailability. As such, there is a metaphorical landfill of drugs/drug-like molecules waiting to be salvaged from the scrapheap and recycled for another indication. Here we describe our eco-friendly mission to deliver new therapeutics for cancer from old drugs.
- Screening roundtable
(Volker Eckelt, Multimode Detection Global Portfolio Director PerkinElmer / Dirk Ullmann, Executive Vice President Lead Discovery Evotec / Moderated by Luke Alderwick, Molecular Microbiology, School of Biosciences, University of Birmingham)
This Screening In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
BMG LABTECH, Cellular Dynamics, Evotec AG, Franhofer ScreeningPort, PerkinElmer Inc., The Beatson Institute for Cancer Research, Trinity College Dublin, University of Birmingham
Alice Vajda, Anthony Davies, Dirk Ullmann, Emma J. Shanks, Laure Marignol, Luke Alderwick, Sarah Louise Ryan, Sheraz Gul, Volker Eckelt
Useful tool to study indepth of any active ingradient